NCT02485912View on ClinicalTrials.gov

Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

ChAd3-EBO Z

This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein

BIOLOGICAL

MVA-EBO Z

This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein

Trial Locations (1)

BP 7325

Centre Hospitalier Universitaire le Dantec, Dakar

All Listed Sponsors
collaborator

Centre Hospitalier Universitaire le Dantec (CHUD), Dakar, Senegal

UNKNOWN

lead

University of Oxford

OTHER

NCT02485912 - Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination | Biotech Hunter | Biotech Hunter